Syntekabio Unveils Language Model SaaS for the First Time at JP Morgan Healthcare Conference

ShinTekka Bio (CEO Jeong Jong-seon), an AI new drug development specialist company, will attend the JP Morgan Healthcare Conference to conduct partnering with more than 30 companies and unveil its language model SaaS for the first time.

ShinTekka Bio announced on the 13th that it will participate in the ‘2025 JP Morgan Healthcare Conference’ and ‘Biotech Showcase 2025’ held in San Francisco, USA, to conduct partnering meetings.

ShinTekka Bio will participate in BIO Partnering at JPM and Biotech Showcase held alongside the JP Morgan Healthcare Conference. Through this, it will introduce its ‘end-to-end AI new drug platform’ and ‘next-generation fusion language model-based virtual screening of 10 billion compounds’ as software as a service (SaaS) targeting global pharmaceutical companies and biotechs, and engage in partnering to secure potential collaborators. In particular, Junhyuk Choi, head of the New York branch, and local team members, along with CEO Jeong Jong-seon from Korea, will directly attend and participate in partnering.

The characteristic of the JPM conference is that investment attraction and networking based on already developed substances are the main activities, making it the largest marketing target market for many investors, ventures, and global pharmaceutical companies. Led by the US branch located in New York, ShinTekka Bio has already booked 35 partnering meetings with pharmaceutical companies in advance, expecting 15 of them to be important meetings. Additionally, many meetings with institutions that were already in pre-negotiation are included, which is seen as a positive signal.

ShinTekka Bio stated that its position participating in this JP Morgan Healthcare Conference is very different from before. The imminent launch of its AI new drug platform capable of ‘infinite repeated searches until effective substances based on language models with global competitiveness emerge’ makes it advantageous to persuade partnering companies, and it has many excellent foreign team members trained in business development in English-speaking countries such as the US and Europe, raising expectations even higher.

The language model platform being introduced this time is a ‘next-generation fusion AI language model-based platform’ set up to infinitely generate effective substances for disease targets based on bio big data including 200 million protein structures predicted by Google AlphaFold, all known 3D structure bank data, and a compound library of over 10 billion compounds.

Jeong Jong-seon, CEO of ShinTekka Bio, said, “Starting with this JP Morgan Healthcare-Biotech Showcase, we will make every effort to secure all business opportunities at global conferences and partnering events this year,” adding, “The newly prepared SaaS is modularized so that clients can use only the platform services they want, lowering the entry barrier to the AI new drug platform service and increasing accessibility, which is expected to lead to more client adoption attempts.”

This content was produced with the assistance of AI translation services.